Treatment with azlocillin in complicated urinary tract infections.
20 patients, aged 18-84 years, with complicated urinary tract infections admitted to hospital were treated with 6-[(R)-2-(2-oxo-imidazolidine-1-carboxamido)-2-phenyl-acetamido]-penicillanic acid sodium salt (azlocillin, Securopen) for 5 to 10 days. Isolated bacteria were Pseudomonas aeruginosa (14), Proteus mirabilis (3), Escherichia coli (2) and Klebsiella spp. (1). Serum concentrations and urine recovery were measured on the fifth day of treatment. The mean serum half-life was 1.85 h and the mean value of the urine recovery 47% of the single dose. Tissue concentrations were analyzed in one patient. The samples were taken 3 h after the infusion. The azlocillin concentration of the renal cortex, 60 microgram/g, was six times higher than the corresponding serum concentration. On the 5th day of treatment the urine was sterile in 80% of the patients. In 12 patients (60%) the urine was still sterile when controlled 2-6 months later. Three patients were treated twice and bacteriologically cured after each period. No sign of sensitization was seen. Side-effects were not reported.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001390:Azlocillin; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D010406:Penicillins / Q000378:metabolism / Q000627:therapeutic use*; D014018:Tissue Distribution; D014552:Urinary Tract Infections / Q000150:complications / Q000188:drug therapy*
D010406:Penicillins; D001390:Azlocillin